The
#FDA has accepted the biologics license application resubmission for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.
www.targetedonc.com/view/fda-acc...
FDA Accepts Narsoplimab BLA Resubmission for Transplant-Associated TMA
The resubmitted biologics license application for narsoplimab in transplant-associated thrombotic microangiopathy has been accepted by the FDA.
